MK436 is a therapeutic agent and an anti-protozoal drug. It is found to be effective against Trypanosoma cruzi infections. References: Jennings FW, Atouguia JM, Murray M. Topical chemotherapy for experimental murine African CNS-trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436. Trop Med Int Health. 1996 Oct;1(5):590-8. PubMed PMID: 8911443. 2: Jennings FW. Chemotherapy of CNS-trypanosomiasis: combination chemotherapy with a 5-nitroimidazole (MK 436), an arsenical (Cymelarsan) and suramin. Trop Med Parasitol. 1991 Sep;42(3):157-60. PubMed PMID: 1801135. 3: Andrade SG, Silva RC, Santiago CM. Treatment of chronic experimental Trypanosoma cruzi infections in mice with MK-436, a 2-substituted 5-nitroimidazole. Bull World Health Organ. 1989;67(5):509-14. PubMed PMID: 2515007; PubMed Central PMCID: PMC2491297. 4: Andrade SG, Silva RC, Santiago CM, Freitas LA. Therapeutic action of MK-436 (2,5-nitroimidazole) on Trypanosoma cruzi infections in mice: a parasitological, serological, histopathological, and ultrastructural study. Bull World Health Organ. 1987;65(5):625-33. PubMed PMID: 3123082; PubMed Central PMCID: PMC2491062. 5: Murray PK, Habbersett MC, Meurer RD. Trypanosoma cruzi: efficacy of the 2-substituted, 5-nitroimidazoles, MK-436 and L634,549, in tissue culture and mice. Am J Trop Med Hyg. 1983 Nov;32(6):1242-50. PubMed PMID: 6418014.

纯度：≥98%

CAS：33450-08-7